Troutman Pepper Advises Eupraxia Pharmaceuticals in Closing of a Non-Brokered Private Placement
November 08, 2024
November 08, 2024
ATLANTA, Georgia, Nov. 8 -- Troutman Pepper, a law firm, issued the following news:
WASHINGTON, D.C. - Troutman Pepper client Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, recently announced that it has completed a non-brokered private placement of 8,905,638 Series 1 Preferred shares of the Company, at a price of C$5.00 per Preferred Share . . .
WASHINGTON, D.C. - Troutman Pepper client Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, recently announced that it has completed a non-brokered private placement of 8,905,638 Series 1 Preferred shares of the Company, at a price of C$5.00 per Preferred Share . . .